Cartesian Therapeutics, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- A key executive is leavingSince May 26, 2026+2.3
Trials
- RNACCartesian Therapeutics2Calm
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Running, no new patientsPhase 3128 patientsMain results: Dec 30, 2026 - RNACCartesian Therapeutics2Calm
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Running, no new patientsPhase 230 patientsMain results: Jan 5, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
May 26, 2026
“On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.”
Read the filing ↗
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.